Loading grant details…
BEhavioral and Adherence Model for improving quality, health outcomes and cost-Effectiveness of healthcaRe
| Funder | European Commission |
|---|---|
| Recipient Organization | Universidad Politecnica de Madrid |
| Country | Spain |
| Start Date | Sep 01, 2021 |
| End Date | Aug 31, 2026 |
| Duration | 1,825 days |
| Number of Grantees | 31 |
| Roles | Participant; Third Party; Coordinator |
| Data Source | European Commission |
| Grant ID | 101034369 |
Grant Description
The main objective of the Project is to create BEAMER, a disease-agnostic behavioral and adherence model for improving quality, health outcomes and cost-effectiveness of healthcare, through improving the quality of life of individuals, enhance healthcare accessibility and sustainability.
The model will allow for tailoring to individual?s needs, using Real World Data captured from patients? behaviors and health system information, transforming the way healthcare stakeholders engage with patients to optimize understanding of their condition and adherence levels throughout their patient journey.
BEAMER is driven by a set of Ontology, Epistemology and Methodology principles, supported by Artificial Intelligence, Natural Language Processing, and Machine Learning.
BEAMER will optimize the disease-agnostic adherence model by real-life testing proof-of-concept in 18 different pilots in Norway, Spain, the Netherlands, Germany, Portugal, and Italy, including over 18,000 patients (3000 patients in each thematic area).
BEAMER will be embodied in an open source European searchable database, continuously updated, validated and optimized by empirical evidence and new insights, available to all stakeholders and adaptable for future developments in healthcare.
Finally, extensive efforts will be directed to develop and implement dissemination and communication activities that increase exploitation and sustainability of BEAMER.
All Grantees
Empirica Gesellschaft Fur Kommunikations Und Technologieforschung Mbh; Fondazione Italiana Sclerosi Multipla - Fism Ets; Heinrich-Heine-Universitaet Duesseldorf; Pfizer Limited; Fundacion Para la Investigacion E Innovacion Biosanitaria de Atencion Primaria; Klinikum Der Universitaet Zu Koeln; Ethniko Kentro Erevnas Kai Technologikis Anaptyxis; Takeda Pharmaceuticals International Ag; Fundacio Institut Universitari Pera la Recerca A L'Atencio Primaria de Salut Jordi Gol I Gurina; Associacao Protectora Dos Diabeticos de Portugal; Echalliance Company Limited By Guarantee; Servicio Madrileno de Salud; Merck Kommanditgesellschaft Auf Aktien; Servier Affaires Medicales; Astellas Pharma Europe Bv; Udg Alliance; Link2Trials Bv; Universitetet I Oslo; Open Evidence; Stichting World Duchenne Organization; Universidade Do Porto; Tilburg University- Universiteit Van Tilburg; Predictby Research and Consulting S.L.; Mysphera Sl; Innovation Sprint; Akershus Universitetssykehus Hf; Novo Nordisk A/S; Fundacion Para la Investigacion Biomedica Hospital Infantil Universitario Nino Jesus; Universidad Politecnica de Madrid; Janssen Pharmaceutica Nv; Medida - Servicos Em Medicina, Educacao, Investigacao, Desenvolvimento E Avaliacao
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
